Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — 16th Bioshares Biotech Summit 2022
23 slides from Amplia Therapeutics's conference presentation, May 12, 2022
Slide 1: Amplia Therapeutics to Present at 16th Bioshares Biotech Summit
ABN 16 165 160 841 ASX RELEASE 12 May 2022 For personal use only Amplia Therapeutics to Present at 16th Bioshares Biotech Summit Amplia Therapeutics Limited (ASX: ATX) today announced that the Company will present at the Bioshares Biotech Summit on Thursday, May 12th, 2022 in Albury, NSW. A copy of
Slide 2: A New Approach to Cancer Therapy
For personal use only ampliatx.com A New Approach to Cancer Therapy BioShares Conference 2022
Slide 3: Disclaimer
Disclaimer The information contained in the presentation is not intended to be an offer for subscription, invitation or For personal use only recommendation with respect to shares of Amplia Therapeutics Limited (“Amplia”) in any jurisdiction. No representation or warranty, express or implied, is mad
Slide 4: Introducing Amplia
For personal use only Introducing Amplia ASX: ATX Melbourne-based Developing inhibitors of Focal Adhesion Kinase (FAK) Oncology Fibrosis Clinical stage (Phase 2) First-line advanced pancreatic cancer 3
Slide 5: Origins of Amplia's FAK Inhibitors
Origins of Amplia's FAK Inhibitors For personal use only FAK PRMT5 MOZ STING and ENPP1 4
Slide 6: Amplia's Pipeline
Amplia’s Pipeline Current Status Next 12- months For personal use only Drug Indication Therapy Preclinical Phase 1 Phase 2 Phase 3 (approval) AMP945 Pancreatic Combination Cancer Therapy Idiopathic AMP945 pulmonary Monotherapy fibrosis (IPF) Cancers & Combo/ AMP945 fibrotic disease Monotherapies AM
Slide 7: Company Snapshot
Company Snapshot For personal use only ATX Price and volume – 6 monthsto 30 April 2022 SHARES | 194m MARKET CAP | $23m CASH | $14.6m LAST QUARTER BURN | $2.3m INSTITUTIONS | Platinum Inv. Management 17.5%; PRICE | $0.12 Blueflag Holdings 7.0%; 12-MONTH HIGH | $0.35 Acorn Capital 6.5%. AV DAILY VOLU
Slide 8: Agenda
Agenda For personal use only 1 Background 2 Why is FAK a good target? 3 Preclinical results 4 Clinical program 5 Commercialisation strategy 7
Slide 9: Amplia's Drug Target | Focal Adhesion Kinase
Amplia’s Drug Target | Focal Adhesion Kinase For personal use only Collagen deposition Fibrosis Collagen crosslinking Immunosupression Focal Adhesion Fibrotic tumour Fibrotic Tissue Kinase (FAK) microenvironment Fibrotic Diseases Solid Cancers 8
Slide 10: Interest in the tumour microenvironment has grown exponentially
PubMed citations of 'tumour For personal use only microenvironment AND FAK' 15,000 10,000 Interest in the tumour microenvironment (TME) has grown exponentially 5,000 The TME is now an important drug target in oncology Amplia's FAK inhibitors target the TME 0 02 04 06 08 10 12 14 16 18 20 20 20 20 20
Slide 11: Sample references - FAK and the TME
Sample references - FAK and the TME For personal use only 10
Slide 12: Amplia's Hypothesis | Enhancing Chemotherapy
Amplia's Hypothesis | Enhancing Chemotherapy For personal use only Fibrotic shields (TME) protect many solid tumours from chemotherapy Amplia’s FAK inhibitors aim to remove the shield Unshielded tumours should be more susceptible to chemotherapy FAK inhibitor Exposed tumour Dead tumour Fibrotic tu
Slide 13: AMP945 Inhibits Fibrosis
AMP945 Inhibits Fibrosis For personal use only Total collagen decreases Cross-linked collagen is a key component of fibrotic tissues Cross-linked collagen decreases AMP945 inhibits collagen formation and collagen cross-linking in a dose- dependent manner Increasing AMP945 12
Slide 14: AMP945 Improves Survival in Pancreatic Cancer Models
AMP945 Improves Survival in Pancreatic Cancer Models For personal use only KPC Model Vehicle P ≤ 0.001 gemcitabine / nab-paclitaxel P ≤ 0.05 AMP945 / gemcitabine / nab-paclitaxel Days post tumour implantation TKCC-10-LO Orthotopic Model Vehicle P ≤ 0.0001 gemcitabine / nab-paclitaxel P ≤ 0.05 AMP94
Slide 15: AMP945 Clinical Development
For personal use only AMP945 Clinical Development
Slide 16: Phase 1 Trial of AMP945
Phase 1 Trial of AMP945 For personal use only Trial Execution Recruited 56 healthy volunteers aged 18 – 65 Single and multiple ascending doses Single site in Melbourne, Australia Summary of Outcomes Safe and well-tolerated at all doses tested Inhibition of FAK demonstrated in skin biopsies take
Slide 17: ACCENT: Clinical Study of AMP945 in People with Pancreatic Cancer
ACCENT: Clinical Study of AMP945 in People with For personal use only Pancreatic Cancer First-line patients with advanced pancreatic cancer Open label AMP945 added to gemcitabine/nab-paclitaxel standard of care Largest patient cohort Not previously treated with gemcitabine and/or nab-paclitaxel Pri
Slide 18: ACCENT Trial Data Accrual
ACCENT Trial Data Accrual Interim For personal use only Part A Part B1 Analysis Part B2 Dose optimisation Efficacy & safety 17
Slide 19: ACCENT Milestones and Timelines
ACCENT Milestones and Timelines CQ2/3 For personal use only 2024 CQ2/3 2023 Complete analysis CQ1 set 2023 Interim Analysis of CQ3 efficacy and safety 2022 Dose selection CQ2 and early 2022 efficacy Dose escalation and readouts initial efficacy HREC/Governance assessments FPI 18
Slide 20: Commercialisation Strategy
Commercialisation For personal use only Strategy Approval Regulatory approvals in oncology are feasible for small-mid biotechs Amplia is engaging with key regulators early in development of AMP945 Partnering Partnerships & licensing achievable subject to proof-of-concept data Strategic partner engag
Slide 21: Growth Plans for 2022
For personal use only Growth Plans for 2022
Slide 22: Value Drivers
Value Drivers For personal use only Clinical studies Pancreatic cancer Report early results Pulmonary fibrosis Regulatory engagement Pre-IND feedback Expand therapeutic opportunities for AMP945 Cancer Fibrosis Expand pipeline by progression of AMP886 into early development 21
Slide 23: Thank You.
Thank You. For personal use only Amplia Therapeutics Limited ABN 16 165160 841 ASX: ATX info@ampliatx.com ampliatx.com John Lambert Chief Executive Officer john@ampliatx.com
Amplia Therapeutics — 16th Bioshares Biotech Summit 2022 on 6ix